ACADIA Pharmaceuticals Inc. — 2020 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2020; filed February 24, 2021. The filing also presents unaudited quarterly results, including fourth-quarter 2020.
Business context
Acadia is a CNS-focused biopharmaceutical company. NUPLAZID (pimavanserin), approved in the U.S. for hallucinations and delusions associated with Parkinson’s disease psychosis (PDP), was its only marketed product and generated all 2020 revenue. The company is developing pimavanserin for additional indications and advancing trofinetide for Rett syndrome, ACP-044 for pain, and M1 PAM candidates including ACP-319.
Financial performance and liquidity
Amounts below are in millions of dollars except per-share data. Figures are consolidated.
| Metric | 2020 | 2019 | Change / context |
|---|---|---|---|
| Net product sales and total revenue | $441.8 | $339.1 | Up 30.3%; primarily higher NUPLAZID unit sales (up approximately 18%) and higher average gross selling price. |
| Cost of product sales | $10.2 | $11.3 | Approximately 2.3% of sales in 2020 versus 3.3% in 2019. |
| Gross profit | $431.5 | $327.7 | Gross margin approximately 97.7% versus 96.7%. |
| Research and development | $319.1 | $240.4 | Increase included CerSci acquisition-related costs and Vanderbilt license payment. |
| Selling, general and administrative | $388.7 | $325.6 | Increase reflected promotion, DRP launch preparation, and personnel costs. |
| Operating loss | $(286.6) | $(246.5) | Operating expenses exceeded revenue; operating loss was approximately 64.9% of revenue. |
| Net loss | $(281.6) | $(235.3) | Loss widened approximately 19.7%; basic and diluted loss per share was $(1.79), versus $(1.60). |
| Cash used in operating activities | $(136.2) | $(151.1) | Use of cash declined year over year. |
| Cash, cash equivalents and investments | $632.0 | $697.4 | Down $65.4; working capital was $611.6 at year-end 2020. |
Fourth-quarter 2020 revenue was $121.0 million, gross profit $118.5 million, net loss $66.8 million, and loss per share $0.42. In fourth-quarter 2019, revenue was $98.3 million, gross profit $95.3 million, net loss $53.0 million, and loss per share $0.34.
At December 31, 2020, current assets were $717.6 million and current liabilities were $106.0 million. The balance sheet lists no borrowings; reported liabilities included $49.5 million of operating lease liabilities, current and long-term. Cash flows included $192.5 million provided by investing activities, largely reflecting investment maturities, and $81.0 million provided by financing activities, principally employee equity exercises. The company stated existing cash resources were expected to fund planned operations for at least 12 months.
Material changes and notable items
- Revenue rose substantially, while net losses increased as R&D and commercial spending grew.
- R&D expense rose $78.7 million. The company reported $72.7 million of upfront and milestone payments/transaction costs in 2020, including $52.8 million of CerSci upfront consideration and transaction costs and a $10.0 million Vanderbilt upfront payment. CerSci consideration included approximately $44.3 million in Acadia shares; additional milestone and royalty obligations may apply.
- Four U.S. customers accounted for approximately 74% of 2020 revenue and 75% of year-end accounts receivable, creating customer concentration exposure.
- Acadia reported $90.2 million of 2020 sales-allowance provisions. The estimate for Medicare Part D rebates was identified as a critical audit matter because it depends on assumptions about utilization and payer mix.
Outlook, risks and contingencies
- The FDA accepted Acadia’s supplemental application for pimavanserin in dementia-related psychosis (DRP), with an April 3, 2021 target action date. Approval was not assured. If approved, Acadia planned to expand its sales force and supporting commercial functions.
- Management expected LAVENDER Phase 3 trofinetide results in the fourth quarter of 2021. It also planned Phase 2 studies of ACP-044 in acute pain in the first quarter of 2021 and osteoarthritis pain in the second quarter of 2021. These were forward-looking plans, not reported outcomes.
- Acadia reported that its Phase 3 MDD CLARITY study did not meet its primary endpoint and that it did not plan additional Phase 3 studies for that use at that time. In schizophrenia, ADVANCE met its primary endpoint but not its key secondary endpoint; the company initiated the ADVANCE-2 Phase 3 study in 2020.
- COVID-19 disrupted clinical-trial enrollment and limited some in-person commercial activity. The company said 2020 NUPLAZID sales were not materially affected, but in May 2020 it reduced its 2020 revenue-guidance range by approximately 5% in response to expected pandemic effects. It reported an uninterrupted product supply and more than two years of API and more than nine months of finished product on hand.
- Five generic-drug applicants filed ANDAs for NUPLAZID. Acadia sued alleging infringement of Orange Book-listed patents; a joint trial was scheduled for May 15, 2023. The company also disclosed securities and derivative litigation, for which it could not estimate possible losses and had not accrued amounts beyond incurred attorneys’ fees. Management stated it did not believe the disclosed matters were likely to have a material adverse effect, while noting litigation outcomes were unpredictable.
- The DOJ advised Acadia in October 2020 that it had concluded its investigation into NUPLAZID sales and marketing and would take no further action at that time.
- Acadia reported an accumulated deficit of approximately $2.0 billion and expected losses to continue for the next few years. It disclosed potential aggregate milestone payments of up to $2.2 billion across agreements, contingent on future development, regulatory, and commercial milestones; these were not current liabilities in the contractual-obligations table.
- Principal risks include reliance on NUPLAZID, regulatory and clinical-trial uncertainty, pricing and reimbursement pressure, generic competition and patent outcomes, dependence on third-party manufacturers, customer concentration, and the possibility of future financing needs.
Important facts for investors to verify
- Outcome and timing of FDA review of the DRP application, and any implications for the planned commercial expansion.
- NUPLAZID sales growth, gross-to-net deductions, Medicare Part D rebate estimates, and customer concentration in subsequent periods.
- Progress and results for trofinetide, ADVANCE-2, and ACP-044, along with changes to development priorities or costs.
- Developments in ANDA patent litigation, generic-entry timing, and the remaining patent protection for NUPLAZID.
- Cash burn and liquidity relative to management’s stated funding horizon, including any new financing or material milestone obligations.